These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 4906370)

  • 1. The need for new antituberculous drugs.
    Dahlström G
    Scand J Respir Dis Suppl; 1969; 69():11-3. PubMed ID: 4906370
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hypersensitivity reactions to antituberculous drugs in pulmonary tuberculosis].
    Dukalski J; Stański K
    Gruzlica; 1969 Oct; 37(10):937-41. PubMed ID: 5366986
    [No Abstract]   [Full Text] [Related]  

  • 3. [Reduction of fresh forms of pulmonary tuberculosis by the classical treatment and by combined antibiotics including rifampicin (comparative study of a personal survey)].
    Weill G; Lévy A; Guignon JP; Lecoq H; Friess JM; Maman P
    Rev Tuberc Pneumol (Paris); 1969 Dec; 33(8):1119-25. PubMed ID: 4916253
    [No Abstract]   [Full Text] [Related]  

  • 4. [New drugs in antitubercular therapy].
    Favez G
    Helv Med Acta Suppl; 1969; 49():66-80. PubMed ID: 4912509
    [No Abstract]   [Full Text] [Related]  

  • 5. Duration of allergy to antituberculous drugs (PAS, SM and INH) in tuberculous patients.
    Brown H; Jennings TS; Coleman EO; Bulubash V
    Med Ann Dist Columbia; 1966 Dec; 35(12):652-7 passim. PubMed ID: 5231829
    [No Abstract]   [Full Text] [Related]  

  • 6. [Intermittent method of treatment of patients with pulmonary tuberculosis showing poor tolerance of antitubercular agents].
    Sushkin AG
    Vrach Delo; 1973 Nov; 11():94-7. PubMed ID: 4786944
    [No Abstract]   [Full Text] [Related]  

  • 7. [Intermittent treatment and simplified continuous treatment of newly-detected pulmonary tuberculosis with first-line drugs and limited administration of PAS. II. Analysis of the causes of failure].
    Niemirowska H; Pecyna-Sielewicz J; Stopczyk J; Janowiec M; Banaszkiewicz H; Czerwinski Z; Krakowska M; Kròlikowskd H; Malecki S; Pezinska Z; Pilch Z; Przemyska B; Szustrowa I; Wardowa A
    Gruzlica; 1973 Jul; 41(7):765-75. PubMed ID: 4730977
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical study of various compounds of PAS].
    Potworowska M; Wareska W; Lachowicz E; Pecyna-Sielewicz J; Ambroziak-Miller M
    Gruzlica; 1969 Jul; 37(7):673-80. PubMed ID: 4900504
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical use of capromycin in pulmonary tuberculosis].
    Zierski M; Bek E
    Gruzlica; 1969 Jul; 37(7):649-57. PubMed ID: 4900503
    [No Abstract]   [Full Text] [Related]  

  • 10. [Anaphylactic shock caused by Fintozid].
    Földeş I; Norbert G
    Ftiziologia; 1971; 20(4):429-31. PubMed ID: 5162280
    [No Abstract]   [Full Text] [Related]  

  • 11. [Drug intolerance and depressive states in tubercular patients].
    Scherding JP; Suerinck E
    Rev Tuberc Pneumol (Paris); 1967; 31(1):55-60. PubMed ID: 6037247
    [No Abstract]   [Full Text] [Related]  

  • 12. Tolerance to ethionamid and PAS in original treatment of tuberculous patients.
    Verbist L; Prignot J; Cosemans J; Gyselen A
    Scand J Respir Dis; 1966; 47(4):225-35. PubMed ID: 5182290
    [No Abstract]   [Full Text] [Related]  

  • 13. [Early and late results of treatment of patients with tuberculosis shedding mycobacteria with primary resistance to basic antituberculous drugs].
    Dubrawska H; Gryziecka T; Maceluch-Wojtkowa M; Orzechowska W
    Wiad Lek; 1968 Jan; 21(2):77-80. PubMed ID: 5671874
    [No Abstract]   [Full Text] [Related]  

  • 14. [Reasons for failures in chemotherapy of tuberculosis].
    Dissmann E
    Beitr Klin Erforsch Tuberk Lungenkr; 1968; 138(1):17-24. PubMed ID: 5728639
    [No Abstract]   [Full Text] [Related]  

  • 15. Aspects of the tuberculosis situation in Denmark, especially chemoresistance.
    Kok-Jensen A; Torning K
    Scand J Respir Dis Suppl; 1969; 69():17-20. PubMed ID: 4906371
    [No Abstract]   [Full Text] [Related]  

  • 16. [Possibilities and limitations of multiple chemoantibiotics in treatment of chronic pulmonary tuberculosis].
    Zanotelli F; Perusi O
    G Ital Mal Torace; 1966; 20(6):365-78. PubMed ID: 5997781
    [No Abstract]   [Full Text] [Related]  

  • 17. [Administration of antituberculous drugs to subjects with basic diseases. 3. Clinical studies on the side effects of antituberculous drugs in patients with or without basic diseases, especially drug allergy].
    Onaka A
    Kekkaku; 1987 Dec; 62(12):672-5. PubMed ID: 3448353
    [No Abstract]   [Full Text] [Related]  

  • 18. [Side effects of antibacterial drugs in the clinical course of pulmonary tuberculosis].
    Czkwianianc M; Markiewicz I
    Przegl Lek; 1969 Jun; 25(6):479-81. PubMed ID: 5805095
    [No Abstract]   [Full Text] [Related]  

  • 19. [Primary resistance in adult pulmonary tuberculosis in France. 3d report of the study center on Primary Resistance: 1966-1970].
    Canetti G; Le Lirzin M; Gay P; Thibier R; Kreis B; Grosset J
    Rev Tuberc Pneumol (Paris); 1972; 36(3):337-56. PubMed ID: 5080965
    [No Abstract]   [Full Text] [Related]  

  • 20. [Eosinophilic infiltrations of the lung as a radiologic manifestation of hypersensitivity to streptomycin, PAS and INH].
    Furman Z
    Gruzlica; 1967 Jan; 35(1):65-9. PubMed ID: 6044451
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.